Genetics and epigenetics of sporadic thyroid cancer

被引:39
作者
Dang Vu-Phan [1 ]
Koenig, Ronald J. [1 ]
机构
[1] Univ Michigan, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA
关键词
Anaplastic; BRAF; Follicular; Papillary; PAX8-PPARG; RAS; ACTIVATED-RECEPTOR-GAMMA; HISTONE DEACETYLASE INHIBITOR; NONCODING RNA HOTAIR; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; TYROSINE KINASE ONCOGENES; DELAYS TUMOR PROGRESSION; SODIUM-IODIDE SYMPORTER; CARCINOMA CELL-LINES; BRAF V600E MUTATION; N-RAS MUTATION;
D O I
10.1016/j.mce.2013.07.030
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Thyroid carcinoma is the most common endocrine malignancy, and although the disease generally has an excellent prognosis, therapeutic options are limited for patients not cured by surgery and radioiodine. Thyroid carcinomas commonly contain one of a small number of recurrent genetic mutations. The identification and study of these mutations has led to a deeper understanding of the pathophysiology of this disease and is providing new approaches to diagnosis and therapy. Papillary thyroid carcinomas usually contain an activating mutation in the RAS cascade, most commonly in BRAF and less commonly in RAS itself or through gene fusions that activate RET. A chromosomal translocation that results in production of a PAX8-PPARG fusion protein is found in follicular carcinomas. Anaplastic carcinomas may contain some of the above changes as well as additional mutations. Therapies that are targeted to these mutations are being used in patient care and clinical trials. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:55 / 66
页数:12
相关论文
共 229 条
[1]   Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas [J].
Adeniran, AJ ;
Zhu, ZW ;
Gandhi, M ;
Steward, DL ;
Fidler, JP ;
Giordano, TJ ;
Biddinger, PW ;
Nikiforov, YE .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (02) :216-222
[2]   Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas [J].
Aldred, MA ;
Morrison, C ;
Gimm, O ;
Hoang-Vu, C ;
Krause, U ;
Dralle, H ;
Jhiang, S ;
Eng, C .
ONCOGENE, 2003, 22 (22) :3412-3416
[3]   Ret proto-oncogene rearrangement in thyroid cancer around Semipalatinsk nuclear testing site [J].
Alipov, G ;
Ito, M ;
Prouglo, Y ;
Takamura, N ;
Yamashita, S .
LANCET, 1999, 354 (9189) :1528-1529
[4]   Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors [J].
Arciuch, Valeria G. Antico ;
Russo, Marika A. ;
Dima, Mariavittoria ;
Kang, Kristy S. ;
Dasrath, Florence ;
Liao, Xiao-Hui ;
Refetoff, Samuel ;
Montagna, Cristina ;
Di Cristofano, Antonio .
ONCOTARGET, 2011, 2 (12) :1109-1126
[5]   Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines [J].
Arlot-Bonnemains, Yannick ;
Baldini, Enke ;
Martin, Benedicte ;
Delcros, Jean-Guy ;
Toller, Matteo ;
Curcio, Francesco ;
Ambesi-Impiombato, Francesco S. ;
D'Armiento, Massimino ;
Ulisse, Salvatore .
ENDOCRINE-RELATED CANCER, 2008, 15 (02) :559-568
[6]   PAX8-peroxisome proliferator-activated receptor γ (PPARγ) disrupts normal PAX8 or PPARγ transcriptional function and stimulates follicular thyroid cell growth [J].
Au, AYM ;
McBride, C ;
Wilhelm, KG ;
Koenig, RJ ;
Speller, B ;
Cheung, L ;
Messina, M ;
Wentworth, J ;
Tasevski, V ;
Learoyd, D ;
Robinson, BG ;
Clifton-Bligh, RJ .
ENDOCRINOLOGY, 2006, 147 (01) :367-376
[7]   Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade [J].
Avruch, J ;
Khokhlatchev, A ;
Kyriakis, JM ;
Luo, ZJ ;
Tzivion, G ;
Vavvas, D ;
Zhang, XF .
RECENT PROGRESS IN HORMONE RESEARCH, VOL 56, 2001, 56 :127-155
[8]   Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma [J].
Baitei, Essa Y. ;
Zou, Minjing ;
Al-Mohanna, Futwan ;
Collison, Katharine ;
Alzahrani, Ali S. ;
Farid, Nadir R. ;
Meyer, Brian ;
Shi, Yufei .
JOURNAL OF PATHOLOGY, 2009, 217 (05) :707-715
[9]  
Baldini E, 2012, CLIN TER, V163, pE307
[10]   Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow [J].
Baloch, ZW ;
LiVolsi, VA .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2005, 5 (04) :573-584